Fee Increase for the Administration of SARS-CoV-2 Vaccines, Effective March 15, 2021

| | | | EIICCUIVC IV | 4. 6 15, 1 | <u> </u> | | | | _ |
|----------------|---|---------------|-----------------------|-----------------------|---------------------|---------------------------|---------|---------------------------------|--------------|
| Procedure Code | National Code Description | Provider Type | Provider Specialty | Place of Service | Pricing Modifier | Informational Modifier | MA Fee | Prior Authorization Required | Limits |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | 01 | 183 | 22 | | | \$40.00 | No | once per day |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | 08 | 082 | 49 | | | \$40.00 | No | once per da |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | 09 | All | 11, 12, 31, 32 | | | \$40.00 | No | once per da |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | 24 | All | 11, 31, 32, 99 | | | \$40.00 | No | once per day |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose | 30 | 300 | 65 | | | \$40.00 | No | once per day |

| | mmunization auministration by | Γ | Г | | T . | | Γ | , |
|-------|---|----|-----|-------------|-----|---------|----|--|
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 30 mcg/0.3mL dosage, | | | 11, 12, 31, | | | | |
| 0001A | diluent reconstituted; first dose | 31 | All | 32 | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 30 mcg/0.3mL dosage, | | | | | | | |
| 0001A | diluent reconstituted; first dose | 33 | 335 | 11, 12 | | \$40.00 | No | once per day |
| | | | | | | | | |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 30 mcg/0.3mL dosage, | | | | | | | |
| 0002A | diluent reconstituted; second dose | 01 | 183 | 22 | | \$40.00 | No | once per day |
| | | | | | | | | |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 30 mcg/0.3mL dosage, | | | | | | | |
| 0002A | diluent reconstituted; second dose | 08 | 082 | 49 | | \$40.00 | No | once per day |
| | | | | | | | | |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 30 mcg/0.3mL dosage, | | | 11, 12, 31, | | | | |
| 0002A | diluent reconstituted; second dose | 09 | All | 32 | | \$40.00 | No | once per day |

| | | | <u> </u> | T | Γ | Г | 1 | | 1 |
|-------|--|----|----------|-------------------|---|---|---------|----|--------------|
| 0002A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | 24 | All | 11, 31, 32, 99 | | | \$40.00 | No | once per day |
| 0002A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | 30 | 300 | 65 | | | \$40.00 | No | once per day |
| 0002A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | 31 | All | 11, 12, 31, 32 | | | \$40.00 | No | once per day |
| 0002A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose | 33 | 335 | 11, 12 | | | \$40.00 | No | once per da |
| 0011A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose | | 183 | 22 | | | \$40.00 | No | once per da |

| | | - | | 1 | T | 1 | | |
|-------|--|----|-----|-------------|---|---------|-----|----------------|
| | Immunization administration by intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; | | | | | | | |
| 0011A | first dose | 08 | 082 | 49 | | \$40.00 | No | once per day |
| 0011A | | 08 | 062 | 49 | | 340.00 | INU | Office per day |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | 44 42 24 | | | | |
| 00444 | preservative free, 100 mcg/0.5mL dosage; | 00 | | 11, 12, 31, | | 440.00 | | |
| 0011A | first dose | 09 | All | 32 | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | 11, 31, 32, | | | | |
| 0011A | first dose | 24 | All | 99 | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | | | | | |
| 0011A | first dose | 30 | 300 | 65 | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | 11, 12, 31, | | | | |
| 0011A | first dose | 31 | All | 32 | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | | | | | |
| 0011A | first dose | 33 | 335 | 11, 12 | | \$40.00 | No | once per day |

| | Immunization administration by | | | | | | | | |
|--------|---|----|-------|-------------|-----|---|---------|-------|--------------|
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | | | | | | |
| 0012A | second dose | 01 | 183 | 22 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | | | | | | |
| 0012A | second dose | 08 | 082 | 49 | | | \$40.00 | No | once per day |
| 0012A | | 08 | 082 | 43 | | | Ş40.00 | NO | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | 11, 12, 31, | | | | | |
| 0012A | second dose | 09 | All | 32 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | 11, 31, 32, | | | | | |
| 0012A | second dose | 24 | All | 99 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | | | | | | |
| 0012A | second dose | 30 | 300 | 65 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (Coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, mRNA-LNP, spike protein, | | | | | | | | |
| | preservative free, 100 mcg/0.5mL dosage; | | | 11, 12, 31, | | | | | |
| 0012A | second dose | 31 | All | 32 | | | \$40.00 | No | once per day |
| 0012/1 | 3333.14 4030 | J1 | , 111 | 1 32 | l . | L | y 10.00 | 1 110 | Shee per day |

| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; | | | | | | | |
|----------------|--|----|-----|-------------------|--|---------|----------|--------------|
| 0012A | second dose | 33 | 335 | 11, 12 | | \$40.00 | No | once per day |
| 0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose | 01 | 183 | 22 | | \$40.00 | No | once per day |
| 00244 | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral | 20 | 082 | 49 | | Ć40.00 | N | |
| 0021A 0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose | 08 | All | 11, 12, 31, 32 | | \$40.00 | No No | once per day |
| 0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose | 24 | All | 11, 31, 32, 99 | | \$40.00 | No | once per day |

| | | | T | 1 | T | 1 | | 1 |
|-------|---|----|-----|-------------------|---|---------|----|--------------|
| 0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose | 30 | 300 | 65 | | \$40.00 | No | once per day |
| 0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose | 31 | AII | 11, 12, 31, 32 | | \$40.00 | No | once per day |
| 0021A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose | 33 | 335 | 11, 12 | | \$40.00 | No | once per day |
| 0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose | 01 | 183 | 22 | | \$40.00 | No | once per day |

| | | | г | 1 | 1 | 1 | | T | 1 |
|-------|---|----|-----|-------------------|---|---|---------|----|--------------|
| 0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose | 08 | 082 | 49 | | | \$40.00 | No | once per day |
| 0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose | 09 | All | 11, 12, 31, 32 | | | \$40.00 | No | once per day |
| 0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose | 24 | All | 11, 31, 32, 99 | | | \$40.00 | No | once per day |
| 0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose | 30 | 300 | 65 | | | \$40.00 | No | once per day |

| | | | I | 1 | Γ | T | | 1 1 |
|--------|---|----------|-------|-------------------|----|---------|-----|----------------|
| 0022A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose | 31 | All | 11, 12, 31, 32 | | \$40.00 | No | once per day |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, | | | | | | | |
| | preservative free, 5x1010 viral | | | | | ١. | | |
| 0022A | particles/0.5mL dosage; second dose | 33 | 335 | 11, 12 | | \$40.00 | No | once per day |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, | | | | | | | |
| 0031A | single dose | 01 | 183 | 22 | | \$40.00 | No | once per day |
| 555171 | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, | <u> </u> | 103 | | | 7 10.00 | | since per udy |
| 0031A | single dose | 08 | 082 | 49 | | \$40.00 | No | once per day |
| | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, | | | 11, 12, 31, | | | | |
| 0031A | single dose | 09 | All | 32 | | \$40.00 | No | once per day |
| | anibic dosc | 0.5 | , AII | J. | ļ. | 770.00 | INO | office per day |

| | 1 | | I | 1 | 1 | 1 | <u> </u> | | |
|-------|---|----|-----|-------------|---|---|----------|----|--------------|
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, DNA, spike protein, adenovirus | | | | | | | | |
| | type 26 (Ad26) vector, preservative free, | | | | | | | | |
| | 5x1010 viral particles/0.5mL dosage, | | | 11, 31, 32, | | | | | |
| 0031A | single dose | 24 | All | 99 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, DNA, spike protein, adenovirus | | | | | | | | |
| | type 26 (Ad26) vector, preservative free, | | | | | | | | |
| | 5x1010 viral particles/0.5mL dosage, | | | | | | | | |
| 0031A | single dose | 30 | 300 | 65 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, DNA, spike protein, adenovirus | | | | | | | | |
| | type 26 (Ad26) vector, preservative free, | | | | | | | | |
| | 5x1010 viral particles/0.5mL dosage, | | | 11, 12, 31, | | | | | |
| 0031A | single dose | 31 | All | 32 | | | \$40.00 | No | once per day |
| | Immunization administration by | | | | | | | | |
| | intramuscular injection of severe acute | | | | | | | | |
| | respiratory syndrome coronavirus 2 (SARS- | | | | | | | | |
| | CoV-2) (coronavirus disease [COVID-19]) | | | | | | | | |
| | vaccine, DNA, spike protein, adenovirus | | | | | | | | |
| | type 26 (Ad26) vector, preservative free, | | | | | | | | |
| | 5x1010 viral particles/0.5mL dosage, | | | | | | | | |
| 0031A | single dose | 33 | 335 | 11, 12 | | | \$40.00 | No | once per day |